Strides Pharma Science Ltd

{"amount":4}

{"description":"Strides Pharma kept its $375-400 million North America FY28 target, expects US recovery from H2FY27, and reported Q4 profit up 51% YoY to ₹129.2 crore with a ₹5 final dividend.","url":"https://www.cnbctv18.com/market/strides-pharma-share-price-maintains-usd-400-million-fy28-north-america-target-sees-us-recovery-from-h2fy27-margin-ws-l-19908930.htm","sentiment":"Positive","domain":"CNBCTV18"}

{"description":"Strides Pharma Science reported Q4 FY26 net profit up 51% to Rs 129.28 crore, with revenue at Rs 1,323.47 crore; board recommended a final dividend of Rs 5 per share.","url":"https://money.rediff.com/news/market/strides-pharma-q4-profit-jumps-51-to-rs-129-cr/47235120260518","sentiment":"Positive","domain":"Rediff Money"}

{"description":"Strides Pharma Science Ltd reported a significant increase in Q3 net profit to Rs 208.12 crore for the quarter ending December 31, 2025, up from Rs 90.04 crore a year earlier, driven by sales growth and a one-time property sale income.","url":"https://money.rediff.com/news/market/strides-pharma-q3-profit-jumps-to-rs-208-12-cr/41057820260130","sentiment":"Positive","domain":"Rediff Money"}

{"description":"Strides Pharma's stock surged 10% on January 30, 2026, following a strong Q3 report, with a net profit increase to ₹202 crore and a revenue rise of 3.6% to ₹1,194.6 crore. The company maintains a US business revenue outlook of $400 million by FY 2028, bolstered by growth in regulated markets.","url":"https://www.cnbctv18.com/market/strides-pharma-q3-results-us-sales-guidance-fy28-margins-expand-share-price-surge-19836927.htm","sentiment":"Positive","domain":"CNBCTV18"}

{"description":"Strides Pharma shares surged 10% to an all-time high of ₹1,025 on November 3, 2025, driven by strong trading volumes and a positive outlook from DAM Capital, which maintained a 'Buy' rating with a target of ₹1,250, citing robust growth and profitability.","url":"https://www.cnbctv18.com/market/strides-pharma-shares-rally-to-hit-all-time-high-dam-capital-sees-room-for-re-rating-19738399.htm","sentiment":"Positive","domain":"CNBCTV18"}

{"description":"Strides Pharma's stock surged 15% to an all-time high following a strong Q2 earnings report, highlighting an expanded product portfolio and new customer acquisitions, indicating robust growth potential.","url":"https://www.business-standard.com/markets/news/strides-pharma-spurts-15-hits-all-time-high-on-strong-q2-performance-125103100778_1.html","sentiment":"Positive","domain":"Business Standard"}

{"description":"Strides Pharma's Q2 results showed a 13% stock surge on October 31, 2025, driven by an 82% net profit increase to ₹131.5 crore and a 25.4% EBITDA rise to ₹232 crore. The company maintains its US revenue guidance of $400 million by FY 2027-2028, despite currency challenges.","url":"https://www.cnbctv18.com/market/strides-pharma-q2-results-52-week-high-margin-expansion-us-sales-guidance-share-price-19735700.htm","sentiment":"Positive","domain":"CNBCTV18"}